JP2017505626A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505626A5
JP2017505626A5 JP2016549495A JP2016549495A JP2017505626A5 JP 2017505626 A5 JP2017505626 A5 JP 2017505626A5 JP 2016549495 A JP2016549495 A JP 2016549495A JP 2016549495 A JP2016549495 A JP 2016549495A JP 2017505626 A5 JP2017505626 A5 JP 2017505626A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
expression vector
cells
lentiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505626A (ja
JP6509884B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/013960 external-priority patent/WO2015117027A1/en
Publication of JP2017505626A publication Critical patent/JP2017505626A/ja
Publication of JP2017505626A5 publication Critical patent/JP2017505626A5/ja
Application granted granted Critical
Publication of JP6509884B2 publication Critical patent/JP6509884B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549495A 2014-01-30 2015-01-30 鎌状赤血球病の遺伝子的是正のための改善された胎児ヘモグロビン Active JP6509884B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933788P 2014-01-30 2014-01-30
US61/933,788 2014-01-30
PCT/US2015/013960 WO2015117027A1 (en) 2014-01-30 2015-01-30 An improved fetal hemoglobin for genetic correction of sickle cell disease

Publications (3)

Publication Number Publication Date
JP2017505626A JP2017505626A (ja) 2017-02-23
JP2017505626A5 true JP2017505626A5 (enExample) 2018-03-08
JP6509884B2 JP6509884B2 (ja) 2019-05-08

Family

ID=53757790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016549495A Active JP6509884B2 (ja) 2014-01-30 2015-01-30 鎌状赤血球病の遺伝子的是正のための改善された胎児ヘモグロビン

Country Status (8)

Country Link
US (2) US10072067B2 (enExample)
EP (1) EP3099334B1 (enExample)
JP (1) JP6509884B2 (enExample)
CN (1) CN106456802B (enExample)
AU (2) AU2015210775B2 (enExample)
CA (1) CA2938419C (enExample)
ES (1) ES2747817T3 (enExample)
WO (1) WO2015117027A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456802B (zh) 2014-01-30 2019-10-18 儿童医院医疗中心 一种改进的用于镰状细胞疾病基因校正的胎儿血红蛋白
KR20230030002A (ko) * 2014-09-04 2023-03-03 메모리얼 슬로안 케터링 캔서 센터 헤모글로빈병증 치료용 글로빈 유전자 치료법
US20180325947A1 (en) 2015-10-27 2018-11-15 Children's Hospital Medical Center Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation
CN106497976A (zh) * 2016-10-31 2017-03-15 广东铱科基因科技有限公司 一种用于矫正重症β‑地中海贫血患者自体造血干细胞的HBB基因试剂盒
WO2019018383A1 (en) 2017-07-18 2019-01-24 Calimmune, Inc. COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES
US11970707B2 (en) 2017-09-18 2024-04-30 Children's Hospital Medical Center Strong insulator and uses thereof in gene delivery
CN109722414A (zh) * 2017-10-27 2019-05-07 博雅辑因(北京)生物科技有限公司 一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基
WO2020041647A1 (en) 2018-08-24 2020-02-27 Calimmune, Inc. Vector production in serum free media
WO2020091797A1 (en) * 2018-11-01 2020-05-07 Children's Hospital Medical Center Reduced intensity conditioning with melphalan
WO2020209934A1 (en) 2019-04-11 2020-10-15 Massachusetts Institute Of Technology Novel chimeric antigen receptors and libraries
US20220243224A1 (en) * 2019-04-15 2022-08-04 Children's Hospital Medical Center Viral vector manufacturing methods
CA3140115A1 (en) 2019-05-23 2020-11-26 Massachusetts Institute Of Technology Ligand discovery and gene delivery via retroviral surface display
EP3790545A4 (en) 2019-07-17 2021-07-28 Emmaus Medical, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF SICKLE CLEANEMIA AND THALASSEMIA
IL305411A (en) 2021-02-26 2023-10-01 Kelonia Therapeutics Inc Lymphocyte-targeted lentiviral vectors
WO2024050450A1 (en) 2022-08-31 2024-03-07 Gigamune, Inc. Engineered enveloped vectors and methods of use thereof
US12440564B2 (en) 2023-09-25 2025-10-14 Kelonia Therapeutics, Inc. Compositions for treating cancer
US20250101122A1 (en) 2023-09-25 2025-03-27 Kelonia Therapeutics, Inc. Antigen binding polypeptides
WO2025151744A1 (en) * 2024-01-10 2025-07-17 University Of Tennessee Research Foundation Improved globin and other lentiviral vectors for gene therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172039B1 (en) * 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
JPH07504645A (ja) * 1990-04-16 1995-05-25 アペックス バイオサイエンス インコーポレーテッド 酵母での組換えヘモグロビンの発現
CA2246005A1 (en) 1998-10-01 2000-04-01 Hsc Research And Development Limited Partnership Hybrid genes for gene therapy in erythroid cells
EP1238092B1 (en) * 1999-12-14 2007-01-24 Novartis AG Bovine immunodeficiency virus (biv) based vectors
ES2582028T3 (es) * 2001-06-29 2016-09-08 Sloan-Kettering Institute For Cancer Research Vector que codifica el gen de la globulina humana y uso del mismo en el tratamiento de hemoglobinopatías
CN1759182A (zh) 2002-11-22 2006-04-12 克雷顿研究院 调节基因的组合物和系统
US20070066548A1 (en) * 2003-03-14 2007-03-22 Albert Einstein College Of Medicine Of Yeshiva University Globin variant gene methods and compositions
WO2005030999A1 (en) 2003-09-25 2005-04-07 Dana-Farber Cancer Institute, Inc Methods to detect lineage-specific cells
US7276340B1 (en) * 2004-09-22 2007-10-02 University Of Central Florida Research Foundation, Inc. Age determination from biological stains using messenger RNA profiling analysis
US20090156534A1 (en) * 2007-09-13 2009-06-18 Memorial Sloan-Kettering Cancer Center Globin lentiviral vectors for treatment of disease
CA2760589C (en) * 2009-05-01 2019-08-20 Joseph Collard Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
US20110294114A1 (en) * 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
WO2013043196A1 (en) * 2011-09-23 2013-03-28 Bluebird Bio, Inc. Improved gene therapy methods
CN106456802B (zh) 2014-01-30 2019-10-18 儿童医院医疗中心 一种改进的用于镰状细胞疾病基因校正的胎儿血红蛋白

Similar Documents

Publication Publication Date Title
JP2017505626A5 (enExample)
US11667890B2 (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
AU2018311504B2 (en) Cellular models of and therapies for ocular diseases
Arumugam et al. Improved human β-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element
PH12021552638A1 (en) Compositions useful for treatment of pompe disease
Li et al. In vivo base editing by a single iv vector injection for treatment of hemoglobinopathies
Bueren et al. Advances in the gene therapy of monogenic blood cell diseases
JP2019533434A5 (enExample)
JP2024150536A (ja) Pklrの遺伝子発現増強のための組成物および方法
CN106350541B (zh) 先天性免疫缺陷基因治疗载体构建方法及其用途
EP4368703A1 (en) Mesenchymal stem cell having oxidative stress resistance, preparation method therefor, and use thereof
CN113316637A (zh) 依靠人工反式激活物的选择
CN111235158A (zh) 用于表达重组人β-珠蛋白的病毒载体及其应用
AU2018345536B2 (en) Treating diabetes with genetically modified beta cells
US20230365996A1 (en) Replacement of rag1 for use in therapy
Burnight et al. Gene therapy using stem cells
Petit et al. Gene transfer of two entry inhibitors protects CD4+ T cell from HIV-1 infection in humanized mice
JP2020517289A5 (enExample)
HRP20240806T1 (hr) Metode liječenja reumatoidnog artritisa pomoću rna-vođenog genoma uređivanja hla gena
ES2864731T3 (es) Terapias a base de la telomerasa transcriptasa inversa
CN105018524B (zh) 一种细胞寿命延长及成血管能力增强的人干细胞的制备方法及其试剂盒
US12440579B2 (en) Optimised RAG1 deficient gene therapy
CN116635523A (zh) 用于疗法中的rag1的替代物
Geller et al. In vitro analysis of promoter activity in Müller cells
US20240425851A1 (en) Polynucleotides useful for correcting mutations in the rag1 gene